Meeting Report
2021–2022 Drug Updates in Hematologic Malignancies
Presented by Jenni Tobin, PharmD
From University of Colorado Cancer Center, Blood and Cellular Therapies Center, Aurora, Colorado
Presenter’s disclosure of conflict of interest is found at the end of this article.
J Adv Pract Oncol 2023;14(3):232–235 |
https://doi.org/10.6004/jadpro.2023.14.3.10 |
© 2023 Harborside™
ABSTRACT
During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr. Tobin discussed their unique mechanisms of action, administration, and how to monitor for and manage side effects associated with these new therapeutics.
For access to the full length article, please
sign in.
